Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition

Chapter 1: Overview of guidelines
Chapter 2: Initial Treatment

CQ01
3) Rutledge F. The role of radical hysterectomy in adenocarcinoma of the endometrium. Gynecol Oncol 1974; 2: 331-47 (Level III)
9) 日本産科婦人科学会子宮癌登録委員会：全国子宫体癌調査成績. 第4報. 1989-1990年度症例. 日本産科婦人科学会. 東京, 1999; 32 (Level IV)

CQ02


CQ08


2) Fanning J. Long-term survival of intermediate risk endometrial cancer (Stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001; 82: 371-4 (Level III)


6) Trimble EL, Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998; 71: 340-3 (Level III)


12) Ayhan A, Tuncer R, Tuncer ZS, Yüce K, Küçükali T. Correlation between clinical and histopathologic risk factors and lymph node metastases in early...
endometrial cancer (a multivariate analysis of 183 cases). Int J Gynecol Cancer 1994; 4: 306-9 (Level III)


CQ04

1) Yokoyama Y, Maruyama H, Sato S, Saito Y. Indispensability of pelvic and paraaortic lymphadenectomy in endometrial cancers. Gynecol Oncol 1997; 64: 411-7 (Level III)

Cox multivariate regression models for estimating prognosis of patients with endometrioid adenocarcinoma of the uterine corpus who underwent thorough surgical staging. Int J Cancer 1998; 79: 521-5 (Level III)

3) Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001; 82: 371-4 (Level III)


Am J Obstet Gynecol 2003; 188: 1265-72 (Level III)

CQ05
5) Mangioni C, De Palo G, Marubini E, Del Vecchio M. Surgical pathologic staging in apparent stage I endometrial carcinoma. Int J Gynecol Cancer 1993; 3: 373-84 (Level III)

CQ06
14) 坂口 敦, 新田 慎, 宮原 陽, 園田直子, 末永義人, 大竹秀幸, 他. 婦人科臨床 重複癌 97 例（1985～2000 年）の臨床的検討. 産婦臨床 2002; 85: 120-5 (Level III)
15) 笠川 基, 田村 幸, 塚田清二, 本間 滋, 高橋 威. 子宮体癌における重複癌. 日産婦誌 2000; 52: 756-60 (Level III)
16) Kamikatahira S, Jobo T, Kuramoto H. Endometrial carcinoma with

CQ07  
2) 日本産科婦人科学会，日本病理学会，日本医学放射線学会編. 子宮体癌取扱い規約，改訂第2版. 東京: 金原出版, 1996; 15-8 (規約)  
3) 日本癌治療学会編. 日本癌治療学会リンバ節規約. 東京: 金原出版, 2002; 12-6, 35-6 (規約)  
5) 竹島信宏，栄沢 聡，清水敬生，藤本郁野，山内一弘，荷見勝彦. 子宮体癌骨盤内リンパ節転移に関する研究. 日産婦誌 1994; 46: 883-8 (Level III)  
6) 加藤 清，増田晶子，塩原茂樹，塩沢丹里，折井文香，二階堂敏雄，他. 鼠径部表皮下リンパ節転移を伴った粘膜内子宮体癌の一例. 日婦病理・コルポスコピー会誌 1998; 16: 58 (Level IV)  
10) Aalders JG, Abeler V, Kolstad P. Stage IV endometrial carcinoma: A clinical and histopathological study of 83 patients. Gynecol Oncol 1984; 17: 75-84 (Level III)  

CQ08  
1) 青木照明，平井勝也. 大網切除術. 図説産婦人科 VIEW 16, 胎生の手術，桑原慶紀編. 東京：メジカルビュー社, 1995: 88-94 (Level IV)


CQ09


8) Rockall AG, Sohaib SA, Harisinghani MG, Babar SA, Singh N, Jeyarajah AR,


CQ10


8) Goff BA, Rice LW. Assessment of depth of myometrial invasion in endometrial adenocarcinoma. Gynecol Oncol 1990; 38: 46-8 (Level III)
9) 孫 廷慰，鄭 優增，蔵本博行：子宮体癌の筋層浸潤に関する術中肉眼診断の評価. 日癌治療会誌 1994; 29: 1942-7 (Level III)
CQ11
1) Bjornsson BL, Nelson BE, Reale FR, Rose PG. Accuracy of frozen section for lymph node metastasis in patients undergoing radical hysterectomy for carcinoma of the cervix. Gynecol Oncol 1993; 51: 50-3 (Level III)

CQ12


CQ13


8) Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 1992; 46: 145-9 (Level II)


10) Turner DA, Gershenson DM, Atkinson N, Sneige N, Wharton AT. The
prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 1989; 74: 775-80 (Level III)


CQ14


3) Kadar N, Homesley HD, Malfetano JH. Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extraterine disease. Gynecol Oncol 1992; 46: 145-9 (Level II)


7) 藏本博行、上坊敏子、新井正秀. 子宮体部の悪性腫瘍. F 治療法，i 手術療法. 新女性
CQ15
2) Eltabbakh GH. Analysis of survival after laparoscopy in women with endometrial carcinoma. Cancer 2002; 95: 1894-901 (Level III)
3) Fram KM. Laparoscopically assisted vaginal hysterectomy versus abdominal hysterectomy in stage I endometrial cancer. Int J Gynecol Cancer 2002; 12: 57-61 (Level III)
laparoscopically assisted vaginal hysterectomy. Gynecol Oncol 2001; 80: 378-82 (Level III)
12) Eltabbakh GH, Mount SL. Laparoscopic surgery does not increase the positive peritoneal cytology among women with endometrial carcinoma. Gynecol Oncol 2006; 100: 361-4 (Level III)
13) Muntz HG, Goff BA, Madsen BL, Yon JL. Port-site recurrence after laparoscopic surgery for endometrial carcinoma. Obstet Gynecol 1999; 93: 807-9 (Level IV)

CQ16
3) Lehoczky O, Bósze P, Ungár L, Töttössy B. Stage I endometrial carcinoma: Treatment of nonoperable patients with intracavitary radiation therapy alone. Gynecol Oncol 1991; 43: 211-6 (Level III)
8) 兼安祐子. 子宮体癌. 放射線治療計画ガイドライン 2008. 日本放射線専門医会・医会，日本放射線腫瘍学会，日本医学放射線学会編. 埼玉: 日本放射線科専門医会・医会事務局. 2008; 225-32 (Guideline)
**Chapter 3 Postoperative Adjuvant Therapy**

**I. Radiotherapy**


5) Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: Systematic review and meta-analysis. BJOG 2007; 114: 1313-20 (Level I)


8) Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage—A Gynecologic Oncology Group study. Cancer 1996; 77: 1115-21 (Level III)


CQ18


4) Zaino RJ, Kurman RJ, Diana KL, Morrow CP. Pathologic models to predict outcome for women with endometrial adenocarcinoma: The importance of the distinction between surgical stage and clinical stage–A Gynecologic Oncology Group study. Cancer 1996; 77: 1115-21 (Level III)


9) Ng TY, Perrin LC, Nicklin JL, Cheuk R, Crandon AJ. Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy. Gynecol Oncol 2000; 79: 490-4 (Level III)

10) Fanning J. Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy. Gynecol Oncol 2001; 82: 371-4 (Level III)


CQ19


7) Grigsby PW, Perez CA, Kuske RR, Kao MS, Galakatos AE. Results of therapy, analysis of failures, and prognostic factors for clinical and pathologic stage III adenocarcinoma of the endometrium. Gynecol Oncol 1987; 27: 44-57 (Level III)


CQ20


8) Willett CG, Ooi CJ, Zietman AL, Menon V, Goldberg S, Sands BE, et al. Acute and late toxicity of patients with inflammatory bowel disease undergoing irradiation for


II. Chemotherapy and Hormone Therapy

CQ21


CQ22


8) A randomized phase III study of tumor volume directed pelvic plus or minus para-aortic irradiation followed by cisplatin and doxorubicin or cisplatin, doxorubicin and paclitaxel for advanced endometrial carcinoma. Phase III, GOG study #184. GOGホームページ http://www.gog.org/ (Level IV)

9) JGOG ホームページ http://www.jgog.gr.jp/ (Level IV)


1) Lewis GC Jr, Slack NH, Mortel R, Bross ID. Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 1974; 2: 368-76 (Level III)


5) 佐藤信二，矢嶋 聡，野澤志朗，宇田 川康博，寺島芳輝，他. 子宮体癌に対する補助化学療法としての MPA の有効性に関する研究—子宮体がん化学療法第二次研究. Oncol Chemother 1996; 12: 172-81 (Level III)


Chapter 4 Post-treatment Follow-up
CQ24


2) Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994; 55: 229-33 (Level III)


4) Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ 1997; 157: 879-86 (Level III)


6) 井上正樹. 子宮体癌治療後のフォローアップの個別化. 産婦の実際 2000; 49: 1607-13 (Level IV)


8) 丹野純香, 伊藤 潔, 片平敦子, 岡村智佳子, 八重樫伸生, 岡村州博. わが教室における子宮体癌の管理. 産婦治療 2002; 85: 683-9 (Level IV)


Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol 2007; 107: 124-9 (Level III)

CQ25
5) 佐藤賢一郎, 水内英充, 森 泰宏, 岡村直樹, 遠藤俊明, 伊東英樹, 他. 子宮体癌の再発管理に血中 CA125 値は有用か？ 日産婦誌 1995；47：917-24 (Level IV)
6) 青木大輔, 片岡史夫, 進 伸幸, 野澤志朗. 腫瘍マーカーによる子宮体癌診断の要点. 産婦の実際 2002；51：949-57 (Level III)
7) Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994; 55: 229-33 (Level III)
9) Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ 1997; 157: 879-86 (Level III)
CQ26


11) Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ 1997; 157: 879-86 (Level III)

CQ27
2) Shumsky AG, Stuart GC, Brasher PM, Nation JG, Robertson DI, Sangkarat S. An evaluation of routine follow-up of patients treated for endometrial carcinoma. Gynecol Oncol 1994; 55: 229-33 (Level III)
8) Agboola OO, Grunfeld E, Coyle D, Perry GA. Costs and benefits of routine follow-up after curative treatment for endometrial cancer. CMAJ 1997; 157: 879-86 (Level III)
Chapter 5 Treatment of Advanced and Recurrent Cancer

CQ28


4) Otsuka I, Kubota T, Aso T. Lymphadenectomy and adjuvant therapy in endometrial carcinoma: Role of adjuvant chemotherapy. Br J Cancer 2002; 87: 377-80 (Level Ⅲ)


8) 衛藤貴子, 岡留雅夫, 齋藤俊章, 入江智子, 植田多恵子, 小川伸二, 他. 子宮体癌における臨床的諸問題—進行子宮体癌に対する積極的手術療法に関する検討. 日産婦九州連合会誌 2002; 11: 73-6 (Level Ⅲ)

   http://www.nccn.org/professionals/physician (Guideline)

CQ29


3) Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 1997; 67: 56-60 (Level III)

4) Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: The role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000; 78: 85-91 (Level III)


6) 衛藤貴子, 岡留雅夫, 齋藤俊章, 入江智子, 植田多恵子, 小川伸二, 他. 子宮体癌における臨床的諸問題一進行子宮体癌に対する積極的手術療法に関する検討. 日産婦九州連合会誌 2002; 11: 73-6 (Level III)

7) Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001; 81: 92-9 (Level III)

8) Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol 1999; 74: 465-7 (Level III)


CQ30

1) Le TD, Yamada SD, Rutgers JL, DiSaia PJ. Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol Oncol 1999; 73: 461-3 (Level IV)

2) Fujiwaki R, Takahashi K, Kitao M. Decrease in tumor volume and histologic response to intraarterial neoadjuvant chemotherapy in patients with cervical and endometrial adenocarcinoma. Gynecol Oncol 1997; 65: 258-64 (Level IV)

3) Resnik E, Taxy JB. Neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 1996; 62: 123-7 (Level III)


Kinsella TJ, Bloomer WD, Lavin PT, Knapp RC. Stage II endometrial carcinoma: 10-year follow-up of combined radiation and surgical treatment. Gynecol Oncol 1980; 10: 290-7 (Level III)


CQ31
1) 片渕秀隆. 再発子宮内膜癌. 日産婦誌 2005; 57: N219-22 (Level IV)


CQ34


11) Aalders JG, Abeler V, Kolstad P. Clinical (stage III) as compared to subclinical intrapelvic extraterine tumor spread in endometrial carcinoma: A clinical and histopathological study of 175 patients. Gynecol Oncol 1984: 17: 64-74 (Level Ⅲ)


Quinn MA, Campbell JJ. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol 1989; 32: 1-3 (Level III)


Chapter 6 Fertility-Preserving Treatment


7) Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003; 80: 1315-24 (Level III)


CQ37

5) Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003; 80: 1315-24 (Level III)

6) Niwa K, Tagami K, Lian Z, Onogi K, Mori H, Tamaya T. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 2005; 112: 317-20 (Level III)


CQ38


3) 佐藤信二，矢崎 聰，野澤志朗，宇田川康博，寺島芳輝，西谷 崇，他，子宮体癌に対する補助化学療法としての MPA の有効性に関する研究. 子宮体がん化学療法第二次研究. Oncol Chemother 1996; 12: 172-81 (Level III)

CQ39
1) Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endometrial adenocarcinoma. Fertil Steril 2003; 80: 1315-24 (Level III)


4) Lowe MP, Cooper BC, Sood AK, Davis WA, Syrop CH, Sorosky JI. Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia. Gynecol Oncol 2003; 91: 569-72 (Level IV)


CQ40


Chapter 7 Atypical Endometrial Hyperplasia

CQ41

1) Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997; 90: 434-40 (Level IV)


CQ42

1) Kurman RJ, Norris HJ. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982; 49: 2547-59 (Level III)


Chapter 8 Non endometrioid types

CQ43


2) Geisler JP, Geisler HE, Melton ME, Wiemann MC. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol 1999; 74: 465-7 (Level III)


7) Thomas MB, Mariani A, Cliby WA, Keeney GA, Podratz KC, Dowdy SC. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol 2007; 107: 186-9 (Level III)


CQ44


(UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98: 353-9 (Level III)


CQ45

1) Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006; 94: 642-6 (Level III)

2) Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001; 81: 92-9 (Level III)


4) Moller KA, Gehrig PA, Van Le L, Secord AA, Schorge J. The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol Oncol 2004; 94: 170-4 (Level III)


Chapter 9 Carcinosarcoma and sarcoma

CQ46


CQ47


6) Peters WA 3rd, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcomas and mixed mesodermal tumors. Gynecol Oncol 1989; 34 : 323-7 (Level III)


12) Clayton Smith D, Kenneth Macdonald O, Gaffney DK. The impact of adjuvant radiation therapy on survival in women with uterine carcinosarcoma. Radiother Oncol 2008; 88: 227-32 (Level III)

CQ48


CQ49


14) Dusenbery KE, Potish RA, Judson P. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol Oncol 2004; 94: 191-6 (Level III)


Tabata T, Takeshima N, Hirai Y, Hasumi K. Low-grade endometrial stromal sarcoma with cardiovascular involvement—a report of three cases. Gynecol Oncol 1999; 75: 495-8 (Level IV)

Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: Steroid receptors and response to hormonal therapy. Gynecol Oncol 1990; 39: 364-7 (Level IV)


CQ51

1) Giuntoli RL 2nd, Garrett-Mayer E, Bristow RE, Gostout BS. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma. Gynecol Oncol 2007; 106: 82-8 (Level III)


7) Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1998; 70: 267-71 (Level III)
17) Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, Dörken B, et al. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal...
sarcoma: Single center experience with 10 cases and review of the literature. Gynecol Oncol 2006; 101: 464-9 \( \text{Level IV} \)


22) Peters WA 3rd, Rivkin SE, Smith MR, Tesh DE. Cisplatin and adriamycin combination chemotherapy for uterine stromal sarcoma and mixed mesodermal tumors. Gynecol Oncol 1989; 34: 323-7 \( \text{Level III} \)

23) Yamawaki T, Shimizu Y, Hasumi K. Treatment of stage IV "high grade" endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin. Gynecol Oncol 1997; 64: 265-9 \( \text{Level IV} \)